GMDAQ vs. COEP, ONVO, GENE, CHRO, SRNE, TTNP, CELZ, FRTX, KRBP, and NSTGQ
Should you be buying Gamida Cell stock or one of its competitors? The main competitors of Gamida Cell include Coeptis Therapeutics (COEP), Organovo (ONVO), Genetic Technologies (GENE), Chromocell Therapeutics (CHRO), Sorrento Therapeutics (SRNE), Titan Pharmaceuticals (TTNP), Creative Medical Technology (CELZ), Fresh Tracks Therapeutics (FRTX), Kiromic BioPharma (KRBP), and NanoString Technologies (NSTGQ). These companies are all part of the "biological products, except diagnostic" industry.
Gamida Cell (NASDAQ:GMDAQ) and Coeptis Therapeutics (NASDAQ:COEP) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, valuation, institutional ownership, profitability, analyst recommendations and community ranking.
50.3% of Gamida Cell shares are owned by institutional investors. Comparatively, 13.9% of Coeptis Therapeutics shares are owned by institutional investors. 6.7% of Gamida Cell shares are owned by company insiders. Comparatively, 21.5% of Coeptis Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Coeptis Therapeutics received 5 more outperform votes than Gamida Cell when rated by MarketBeat users.
In the previous week, Coeptis Therapeutics had 3 more articles in the media than Gamida Cell. MarketBeat recorded 3 mentions for Coeptis Therapeutics and 0 mentions for Gamida Cell. Coeptis Therapeutics' average media sentiment score of 0.96 beat Gamida Cell's score of 0.00 indicating that Coeptis Therapeutics is being referred to more favorably in the news media.
Coeptis Therapeutics has a consensus target price of $3.00, suggesting a potential upside of 1,009.47%. Given Coeptis Therapeutics' higher possible upside, analysts clearly believe Coeptis Therapeutics is more favorable than Gamida Cell.
Coeptis Therapeutics has lower revenue, but higher earnings than Gamida Cell. Coeptis Therapeutics is trading at a lower price-to-earnings ratio than Gamida Cell, indicating that it is currently the more affordable of the two stocks.
Gamida Cell's return on equity of 0.00% beat Coeptis Therapeutics' return on equity.
Gamida Cell has a beta of 1.14, indicating that its share price is 14% more volatile than the S&P 500. Comparatively, Coeptis Therapeutics has a beta of -0.92, indicating that its share price is 192% less volatile than the S&P 500.
Summary
Coeptis Therapeutics beats Gamida Cell on 8 of the 15 factors compared between the two stocks.
Get Gamida Cell News Delivered to You Automatically
Sign up to receive the latest news and ratings for GMDAQ and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GMDAQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
GMDAQ vs. The Competition
Gamida Cell Competitors List
Related Companies and Tools
